Welcome to our dedicated page for AIM ImmunoTech SEC filings (Ticker: AIMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AIM ImmunoTech Inc. (AIMI/AIM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a smaller reporting biotechnology issuer focused on immuno-pharma therapeutics. AIM ImmunoTech files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A and other forms that document its financial condition, governance decisions and material events.
For investors tracking AIM ImmunoTech’s development-stage biotechnology business, the company’s periodic reports are central. The Form 10-K and Form 10-Q filings describe its status as a smaller reporting company, summarize its focus on therapeutics for cancers, immune disorders and viral diseases, and provide financial statements that reflect revenues and net losses consistent with a research-focused enterprise. A Form 12b-25 (Notification of Late Filing) for the quarter ended September 30, 2025 explains delays in completing the required review, outlines the expectation to file within the permitted extension period and describes anticipated changes in revenues, net loss and loss per share compared to prior-year periods.
AIM ImmunoTech also uses Form 8-K to report material events. Examples include furnishing a corporate presentation under Regulation FD, disclosing NYSE American notices of noncompliance with minimum stockholders’ equity requirements and the acceptance of a plan to regain compliance, and filing its Certificate of Incorporation as amended and restated as an exhibit. These current reports help investors understand exchange listing issues, governance documents and other significant developments beyond routine financial reporting.
Proxy statements on Schedule 14A, such as the definitive proxy for the 2025 Annual Meeting of Stockholders, provide detail on board elections, advisory votes on executive compensation, auditor ratification and the company’s use of scaled disclosure obligations as a smaller reporting company. Voting results for proposals, reported via Form 8-K, show how stockholders have voted on directors, compensation matters and the frequency of advisory votes.
On Stock Titan, AIM ImmunoTech’s filings are updated as they appear on EDGAR, and AI-powered tools summarize key points from lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements. This helps users quickly identify information on topics such as financial performance trends, exchange compliance, governance decisions and material agreements, while still allowing access to the full original filings for detailed review. Form 4 insider transaction data, when filed, can also be monitored alongside these core disclosures to give a fuller picture of corporate activity.
AIM ImmunoTech Inc. reported that it filed its amended and restated Certificate of Incorporation as Exhibit 3.1(i). The updated certificate is consolidated through October 29, 2025 and supersedes prior exhibit pieces.
The filing lists exhibits under Item 9.01 and includes the Cover Page Inline XBRL file. AIM’s common stock trades on the NYSE American under the symbol AIM.
AIM ImmunoTech Inc. filed its definitive proxy for the 2025 Annual Meeting. The virtual meeting is set for December 16, 2025 at 11:00 a.m. Eastern Time. Stockholders of record at the close of business on October 24, 2025 may vote; shares outstanding and entitled to vote were 2,764,188 as of the record date.
The Board recommends voting FOR all five director nominees—Nancy K. Bryan, Thomas K. Equels, Ted D. Kellner, David I. Chemerow and William M. Mitchell—FOR ratification of BDO USA, P.C. as independent auditor for the fiscal year ending December 31, 2025, FOR approval, on an advisory basis, of named executive officer compensation, and selecting 1 YEAR for the frequency of future say‑on‑pay votes.
Directors will be elected by a plurality of votes cast; Proposals 2–4 require a majority in voting power of shares represented and entitled to vote. Quorum is 33 and 1/3% of shares entitled to vote. Proxies are being solicited by the Board; Sodali & Co. has been engaged to assist, for a fee of $20,000 plus expenses. AIM notes it is a smaller reporting company using scaled disclosures. Materials, including the 2024 Form 10‑K, are available via the company’s website and the SEC.